179 related articles for article (PubMed ID: 36840001)
1. A Physiologically Based Pharmacokinetic Model of Ketoconazole and Its Metabolites as Drug-Drug Interaction Perpetrators.
Marok FZ; Wojtyniak JG; Fuhr LM; Selzer D; Schwab M; Weiss J; Haefeli WE; Lehr T
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36840001
[TBL] [Abstract][Full Text] [Related]
2. Physiologically based pharmacokinetic modeling of imatinib and N-desmethyl imatinib for drug-drug interaction predictions.
Loer HLH; Kovar C; Rüdesheim S; Marok FZ; Fuhr LM; Selzer D; Schwab M; Lehr T
CPT Pharmacometrics Syst Pharmacol; 2024 Jun; 13(6):926-940. PubMed ID: 38482980
[TBL] [Abstract][Full Text] [Related]
3. A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug-Drug Interaction Modeling.
Fuhr LM; Marok FZ; Mees M; Mahfoud F; Selzer D; Lehr T
Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890369
[TBL] [Abstract][Full Text] [Related]
4. Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.
Umehara K; Huth F; Jin Y; Schiller H; Aslanis V; Heimbach T; He H
Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145690
[TBL] [Abstract][Full Text] [Related]
5. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
Prakash C; Fan B; Ke A; Le K; Yang H
Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634
[TBL] [Abstract][Full Text] [Related]
6. Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug-Drug-Gene Interaction Predictions.
Loer HLH; Türk D; Gómez-Mantilla JD; Selzer D; Lehr T
Pharmaceutics; 2022 Apr; 14(5):. PubMed ID: 35631502
[TBL] [Abstract][Full Text] [Related]
7. Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions.
Hanke N; Gómez-Mantilla JD; Ishiguro N; Stopfer P; Nock V
Pharm Res; 2021 Oct; 38(10):1645-1661. PubMed ID: 34664206
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and Its Drug-Drug Interaction Potential: A Physiologically Based Pharmacokinetic Modeling Approach.
Fuhr LM; Marok FZ; Hanke N; Selzer D; Lehr T
Pharmaceutics; 2021 Feb; 13(2):. PubMed ID: 33671323
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin.
Gu H; Dutreix C; Rebello S; Ouatas T; Wang L; Chun DY; Einolf HJ; He H
Drug Metab Dispos; 2018 Feb; 46(2):109-121. PubMed ID: 29117990
[TBL] [Abstract][Full Text] [Related]
10. Prediction of Drug-Drug Interaction Potential of Tegoprazan Using Physiologically Based Pharmacokinetic Modeling and Simulation.
Yoon DY; Lee S; Jang IJ; Kim M; Lee H; Kim S; Kim B; Song GS; Rhee SJ
Pharmaceutics; 2021 Sep; 13(9):. PubMed ID: 34575565
[TBL] [Abstract][Full Text] [Related]
11. Physiologically based pharmacokinetic modelling of oxycodone drug-drug interactions.
Rytkönen J; Ranta VP; Kokki M; Kokki H; Hautajärvi H; Rinne V; Heikkinen AT
Biopharm Drug Dispos; 2020 Feb; 41(1-2):72-88. PubMed ID: 31925778
[TBL] [Abstract][Full Text] [Related]
12. A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions.
Li X; Frechen S; Moj D; Lehr T; Taubert M; Hsin CH; Mikus G; Neuvonen PJ; Olkkola KT; Saari TI; Fuhr U
Clin Pharmacokinet; 2020 Jun; 59(6):781-808. PubMed ID: 31853755
[TBL] [Abstract][Full Text] [Related]
13. Quantitative Assessment of Elagolix Enzyme-Transporter Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling.
Chiney MS; Ng J; Gibbs JP; Shebley M
Clin Pharmacokinet; 2020 May; 59(5):617-627. PubMed ID: 31713224
[TBL] [Abstract][Full Text] [Related]
14. Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens.
Moj D; Hanke N; Britz H; Frechen S; Kanacher T; Wendl T; Haefeli WE; Lehr T
AAPS J; 2017 Jan; 19(1):298-312. PubMed ID: 27822600
[TBL] [Abstract][Full Text] [Related]
15. Physiologically based pharmacokinetic model to predict drug-drug interactions with the antibody-drug conjugate enfortumab vedotin.
Choules MP; Zuo P; Otsuka Y; Garg A; Tang M; Bonate P
J Pharmacokinet Pharmacodyn; 2023 Aug; ():. PubMed ID: 37632598
[TBL] [Abstract][Full Text] [Related]
16. Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib.
Wu F; Krishna G; Surapaneni S
Cancer Chemother Pharmacol; 2020 Oct; 86(4):461-473. PubMed ID: 32886148
[TBL] [Abstract][Full Text] [Related]
17. Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole.
Türk D; Hanke N; Wolf S; Frechen S; Eissing T; Wendl T; Schwab M; Lehr T
Clin Pharmacokinet; 2019 Dec; 58(12):1595-1607. PubMed ID: 31129789
[TBL] [Abstract][Full Text] [Related]
18. Development and verification of a physiologically based pharmacokinetic model of dronedarone and its active metabolite N-desbutyldronedarone: Application to prospective simulation of complex drug-drug interaction with rivaroxaban.
Leow JWH; Ang XJ; Chan ECY
Br J Clin Pharmacol; 2023 Jun; 89(6):1873-1890. PubMed ID: 36683488
[TBL] [Abstract][Full Text] [Related]
19. Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model.
Xue C; Zhang X; Cai W
Pharmaceutics; 2017 Dec; 10(1):. PubMed ID: 29267251
[TBL] [Abstract][Full Text] [Related]
20. Predicting the Drug-Drug Interaction Mediated by CYP3A4 Inhibition: Method Development and Performance Evaluation.
Ren HC; Sai Y; Chen T; Zhang C; Tang L; Yang CG
AAPS J; 2021 Dec; 24(1):12. PubMed ID: 34893925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]